Table 3 Novel Targeted Therapies for CNS Lymphoma
From: Current and emerging therapies for primary central nervous system lymphoma
Author | Year | Diagnosis | N | Study | Age (year) | Regimen | Outcome |
|---|---|---|---|---|---|---|---|
BTKi | |||||||
 Grommes C. et al [70] | 2017 | PCNSL/SCNSL, r/r | 20 | phase I | 21-85 | ibrutinib monotherapy | ORR: 10/13, CR 5, PR 5 |
 Lionakis MS. et al [14] | 2017 | PCNSL, ND and r/r | 18 | phase Ib | 49-87 | ibrutinib + DA-TEDDi-R | CR+CRu 16/18 |
2019 | PCNSL/PVRL, r/r | 52 | phase II | 47-82 | ibrutinib monotherapy | ORR: 59%, mean PFS 4.8m, mean OS 19.2m | |
 Grommes C. et al [72] | 2019 | PCNSL/SCNSL, r/r | 15 | phase Ib | 23-74 | ibrutinib + MTX+R | ORR: 12/15 |
 Chen F. et al [73] | 2020 | PCNSL, ND | 11 | retrospective | 41-68 | Ibrutinib+MTX | ORR 81.8% |
 Narita Y. et al [74] | 2021 | PCNSL, r/r | 44 | phase I/II | 29-86 | tirabrutinib monotherapy | >60% at 320 mg, 100% at 480 mg, and 53% at 480 mg (fasted) |
IMids | |||||||
 Rubenstein JL. et al [42] | 2018 | PCNSL/SCNSL, r/r | 14 | phase I | 47-79 | lenalidomide or lenalidomide +R | ORR: 64% |
 Tun HW. et al [15] | 2018 | PCNSL/PVRL, r/r | 25 | phase I | adults | pomalidomide+DXM | ORR: 48% |
 Vu K. et al [75] | 2019 | PCNSL/SCNSL | 13 | retrospective | 70-86 | lenalidomide in maintenance | mean PFS: not reached |
 Ghesquieres H.et al [76] | 2019 | PCNSL/PVRL, r/r | 50 | phase II | 46-86 | lenalidomide+R | ORR: 35.6% |
PD-1 antibody | |||||||
 Nayak L. et al [77] | 2017 | PCNSL/SCNSL, r/r | 5 | case report | 54-85 | nivolumab+R/WBRT | CR 4, PR 1 |
BBB permeabilization | |||||||
 Ferreri AJM. et al [78] | 2020 | PCNSL, r/r | 28 | phase II | 26-78 | NGR-hTNF/R-CHOP | ORR: 75%; CR 11, PR 10 |
CAR-T | |||||||
 Tu S. et al [79] | 2019 | PCNSL, r/r | 1 | case report | 67 | CD19-CD70 dual CART | CR |
 Abbasi A. et al [80] | 2020 | SCNSL, r/r | 2 | retrospective | NA | axicabtagene ciloleucel | CR 2 |
 Abramson JS. et al [81] | 2020 | SCNSL, r/r | 7 | prospective | NA | lisocabtagene maraleucel | CR 3 (of 6 evaluated) |